Posted by Michael Wonder on 01 Mar 2017
Teva announces priority review granted by FDA for SD-809 for treatment of tardive dyskinesia
28 February 2017 - Teva Pharmaceutical Industries today announced the U.S. FDA has accepted the new drug application and granted priority review for SD-809 (deutetrabenazine) for the treatment of tardive dyskinesia.
The FDA has assigned a Prescription Drug User Fee Act goal date of 30 August 2017.
